2018 Section 6 - Laryngology, Voice Disorders, and Bronchoesophalogy

Otolaryngology–Head and Neck Surgery 00(0)

symptoms in laryngopharyngeal reflux patients. Otolaryngol Head Neck Surg . 2012;146:92-97. 222. Kahrilas PJ, Shaheen NJ, Vaezi MF; American Gastro- enterological Association Institute; Clinical Practice and Quality Management Committee. American Gastroentero- logical Association Institute technical review on the manage- ment of gastroesophageal reflux disease. Gastroenterology . 2008;135:1392-1413, 1413.e1-e5. 223. Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroen- terological Association medical position statement on the man- agement of gastroesophageal reflux disease. Gastroenterology . 2008;135:1383-1391, 1391.e1-e5. 224. Qua CS, Wong CH, Gopala K, et al. Gastro-oesophageal reflux disease in chronic laryngitis: prevalence and response to acid-sup- pressive therapy. Aliment Pharmacol Ther . 2007;25:287-295. 225. Thomas JP, Zubiaur FM. Over-diagnosis of laryngopharyngeal reflux as the cause of hoarseness. Eur Arch Otorhinolaryngol . 2013;270:995-999. 226. Rafii B, Taliercio S, Achlatis S, et al. Incidence of underly- ing laryngeal pathology in patients initially diagnosed with laryngopharyngeal reflux. Laryngoscope . 2014;124:1420- 1424. 227. Sulica L. Hoarseness misattributed to reflux: sources and pat- terns of error. Ann Otol Rhinol Laryngol . 2014;123:442-445. 228. Wright MR, Sharda R, Vaezi MF. Unmet needs in treating laryngo-pharyngeal reflux disease: where do we go from here? Expert Rev Gastroenterol Hepatol . 2016;10:995-1004. 229. Hanlon JT, Landerman LR, Artz MB, et al. Histamine2 recep- tor antagonist use and decline in cognitive function among community dwelling elderly. Pharmacoepidemiol Drug Saf . 2004;13:781-787. 230. Boustani M, Hall KS, Lane KA, et al. The association between cognition and histamine-2 receptor antagonists in African Americans. J Am Geriatr Soc . 2007;55:1248-1253. 231. Gomm W, von Holt K, Thomé F, et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemio- logical claims data analysis. JAMA Neurol . 2016;73:410-416. 232. Freedberg DE, Abrams JA. Clostridium difficile infection in the community: are proton pump inhibitors to blame? World J Gastroenterol . 2013;19:6710-6713. 233. Janarthanan S, Ditah I, Adler DG, et al. Clostridium difficile – associated diarrhea and proton pump inhibitor therapy: a meta- analysis. Am J Gastroenterol . 2012;107:1001-1010. 234. Kim YG, Graham DY, Jang BI. Proton pump inhibitor use and recurrent Clostridium difficile –associated disease: a case- control analysis matched by propensity score. J Clin Gastroen- terol . 2012;46:397-400. 235. Leontiadis GI, Miller MA, Howden CW. How much do PPIs contribute to C difficile infections? Am J Gastroenterol . 2012;107:1020-1021. 236. Garcia Rodriguez LA, Ruigomez A, Panes J. Use of acid- suppressing drugs and the risk of bacterial gastroenteritis. Clin Gastroenterol Hepatol . 2007;5:1418-1423. 237. Ramsay EN, Pratt NL, Ryan P, et al. Proton pump inhibi- tors and the risk of pneumonia: a comparison of cohort and self-controlled case series designs. BMC Med Res Methodol . 2013;13:82.

203. Prince MR, Arnoldus C, Frisoli JK. Nephrotoxicity of high- dose gadolinium compared with iodinated contrast. J Magn Reson Imaging . 1996;6:162-166. 204. Tardy B, Guy C, Barral G, et al. Anaphylactic shock induced by intravenous gadopentetate dimeglumine. Lancet . 1992;22:494. 205. Perazella MA. Gadolinium-contrast toxicity in patients with kidney disease: nephrotoxicity and nephrogenic systemic fibrosis. Curr Drug Saf . 2008;3:67-75. 206. Brummett RE, Talbot JM, Charuhas P. Potential hearing loss resulting from MR imaging. Radiology . 1988;169:539-540. 207. Smith-Bindman R, Miglioretti DL, Larson EB. Rising use of diagnostic medical imaging in a large integrated health system. Health Aff (Millwood) . 2008;27:1491-1502. 208. Saini S, Sharma R, Levine LA, et al. Technical cost of CT examinations. Radiology . 2001;218:172-175. 209. Saini S, Seltzer SE, Bramson RT, et al. Technical cost of radio- logic examinations: analysis across imaging modalities. Radi- ology . 2000;216:269-272. 210. Hopkins C, Yousaf U, Pedersen M. Acid reflux treatment for hoarseness. Cochrane Database Syst Rev . 2006;(1):CD005054. 211. Fass R, Noelck N, Willis MR, et al. The effect of esomeprazole 20 mg twice daily on acoustic and perception parameters of the voice in laryngopharyngeal reflux. Neurogastroenterol Motil- ity . 2010;22:134-141, e44-e45. 212. Vaezi MF, Richter JE, Stasney CR, et al. Treatment of chronic posterior laryngitis with esomeprazole. Laryngoscope . 2006;116:254-260. 213. El-Serag HB, Lee P, Buchner A, et al. Lansoprazole treat- ment of patients with chronic idiopathic laryngitis: a placebo- controlled trial. Am J Gastroenterol . 2001;96:979-983. 214. Noordzij JP, Khidr A, Evans BA, et al. Evaluation of omepra- zole in the treatment of reflux laryngitis: a prospective, placebo-controlled, randomized, double-blind study. Laryngo- scope . 2001;111:2147-2151. 215. Eherer AJ, Habermann W, Hammer HF, et al. Effect of pan- toprazole on the course of reflux-associated laryngitis: a placebo-controlled double-blind crossover study. Scand J Gas- troenterol . 2003;38:462-467. 216. Wo JM, Koopman J, Harrell SP, et al. Double-blind, placebo- controlled trial with single-dose pantoprazole for laryngopha- ryngeal reflux. Am J Gastroenterol . 2006;101:1972-1978. 217. Reichel O, Dressel H, Wiederanders K, et al. Double-blind, placebo-controlled trial with esomeprazole for symptoms and signs associated with laryngopharyngeal reflux. Otolaryngol Head Neck Surg . 2008;139:414-420. 218. Havas T, Huang S, Levy M, et al. Posterior pharyngolaryngi- tis: double-blind randomised placebo-controlled trial of proton pump inhibitor therapy. Australian J Otolaryngol . 1999;3:243. 219. Lam PK, Ng ML, Cheung TK, et al. Rabeprazole is effective in treating laryngopharyngeal reflux in a randomized placebo- controlled trial. Clini Gastroenterol Hepatol . 2010;8:770-776. 220. Steward DL, Wilson KM, Kelly DH, et al. Proton pump inhibitor therapy for chronic laryngo-pharyngitis: a random- ized placebo-control trial. Otolaryngol Head Neck Surg . 2004;131:342-350. 221. Park JO, Shim MR, Hwang YS, et al. Combination of voice therapy and antireflux therapy rapidly recovers voice-related

67